A Case of von Willebrand’s Disease Diagnosed by Refractory Tonsillar Hemorrhage with a Family History

2021 ◽  
Vol 114 (4) ◽  
pp. 291-296
Author(s):  
Ryota Morozumi ◽  
Seiichi Nakano ◽  
Naoki Toda ◽  
Eiji Kondo ◽  
Hidetaka Iwasaki ◽  
...  
Blood ◽  
2008 ◽  
Vol 112 (11) ◽  
pp. 5454-5454
Author(s):  
Gary W Moore ◽  
David A Gurney ◽  
Bella Madan

Abstract Acquired von Willebrand’s disease (AVWD) is a rare bleeding disorder with similar clinical and laboratory findings to the inherited disorder. It can be caused by specific or non-specific antibodies, adsorption of von Willebrand factor (VWF) onto malignant cell clones, hypothyroidism or loss of high molecular weight multimers under conditions of high sheer stress. AVWD is commonly diagnosed using standard laboratory tests for inherited VWD in the absence of a family history of bleeding. In this abstract we present an unusual case of development of antibodies in a 76 year old white caucasian lady with documented desmopressin responsive Type 1 VWD and a family history of VWD. Her baseline laboratory parameters were VWF: Ag of 26.6 IU/dL (RR 45–160 IU/dL), Factor VIII:C of 52.6 IU/dL (RR 50–200 IU/dL) and normal VWF multimer distribution. She presented with undetectable VWF:RCo, VWF:CB 2.9 IU/dL, VWF:Ag 8.2 IU/dL, FVIII:C 8.4 IU/dL and unmeasurable PFA-100 closure times during routine work-up prior to planned elective surgery. There had been no significant change in her clinical symptomatology. The lupus anticoagulant and moderately elevated IgM anticardiolipin antibodies which had been detected three years previously remained positive and a Bethesda assay for FVIII inhibitor was negative. Her rheumatoid factor, antinuclear antibody and double stranded DNA antibody tests were negative. She was extensively investigated for an underlying malignancy but the only positive finding was that of an IgG kappa paraprotein band. The IgG level was 7.5 g/L (RR 6–16 g/L) without any evidence of immune paresis. Assay for VWF:RCo inhibitor on a 1:1 mixture of patient and normal plasma after 5 minute incubation at 37°C was negative. The patient was infused with VWF concentrate Haemate 8000 RCo units and serial assays of VWF:RCo, VWF:Ag and FVIII:C were undertaken. At 10 minutes post-infusion the levels were 173.0, 161.6 and 70.3 IU/dL respectively and 88.2, 131.1 and 39.8 IU/dL respectively at 20 minutes. The VWF:RCo dropped to 10.0 IU/dL by 4 hours whereas the VWF:Ag was 43.1 IU/dL at that point and 27.2 IU/dL at 8 hours, when the VWF:RCo had reduced further to 6.8 IU/dL. The FVIII:C continued to fall until it levelled off at 27.5 IU/dL at 2 hours. The VWF:RCo inhibitor assay was repeated on an incubated 1:1 mixture of patient and normal plasma. The normal plasma was manipulated to have a value at the start of the assay of 130.0 IU/dL once mixed with patient plasma, which fell to 92.0, 87.0 and 78.0 IU/dL after 30 minutes, 4 hours and 18 hours incubation respectively, revealing a progressive inhibitor of VWF:RCo activity. The antibody demonstrated is likely to be an acquired autoantibody rather than an antibody to previously infused von Willebrand factor concentrate as the pre-infusion VWF activity and antigen levels in the patient were undetectable. Also, the additional presence of antiphospholipid antibodies may indicate the inherent propensity of the patient to produce autoantibodies. Further, the additional presence of an IgA paraprotein band may also have contributed to the low VWF activity levels. It is interesting to speculate on the multifactorial nature of the pathogenic mechanism of development of multiple auto-antibodies in this patient. AVWD associated with paraproteinemia is well described. However, in this case the AVWD and paraprotenemia developed on a background of lifelong history of inherited VWD. To our knowledge this is the first reported case of development of acquired antibodies in a patient with pre-existing inherited VWD. Her forthcoming surgery will provide further challenges for management.


Blood ◽  
1968 ◽  
Vol 31 (6) ◽  
pp. 806-812 ◽  
Author(s):  
JOSEPH V. SIMONE ◽  
JO ANN CORNET ◽  
CHARLES F. ABILDGAARD

Abstract A boy is described with clinical and laboratory manifestations which were indistinguishable from von Willebrand’s disease. However, the relatively recent onset of symptoms, the negative family history, and the normal coagulation studies in both parents and six siblings led to the belief that the bleeding syndrome was acquired rather than inherited. The patient subsequently developed systemic lupus erythematosus following a smallpox vaccination. The findings of von Willebrand’s syndrome disappeared following corticosteroid therapy and did not return after cessation of therapy.


1990 ◽  
Vol 64 (01) ◽  
pp. 117-120 ◽  
Author(s):  
Alessandra Casonato ◽  
M Teresa Sartori ◽  
Luigi de Marco ◽  
Antonio Girolami

SummaryWe have investigated the effects of 1-desamino-8-D-arginine vasopressin (DDAVP) infusion on platelet count and bleeding time in 4 patients with type IIB von Willebrand’s disease (vWd). Three of four patients showed a normalization of the bleeding time within 1 h after the infusion, while bleeding time was not modified in the fourth. In accordance with the literature, thrombocytopenia was observed after DDAVP infusion, but this thrombocytopenia was due to the anticoagulants used for blood collection. In two patients (F. I., G. F.) no thrombocytopenia was observed when platelets were counted by fingerstick method but there was a 20% platelet decrease in blood samples collected in sodium citrate and a 50% decrease in samples collected in EDTA. Dramatic falls in platelet counts (70–95%) were observed in the additional two patients (C. A., D.Z.) after DDAVP infusion, when both sodium citrate or EDTA were used as anticoagulants. In the latter two patients there was also a 50% decrease in platelet count when the fingerstick method was used. The decrease in the patient’s platelet count in EDTA samples after DDAVP infusion could be prevented, in part, by the previous additions of an anti GPIb monoclonal antibody and an anti GPIIb-IIIa monoclonal antibody.Thus, the thrombocytopenia observed in the four IIB vWd patients studied after DDAVP infusion seems to be, at least partially, a pseudothrombocytopenia depending on the calcium concentration in the blood samples and the availability of GPIb and GPIIb-IIIa receptors. These findings and the normalization of the bleeding time observed in three of the four patients has led us to reconsider the possible use of DDAVP in the treatment of our IIB vWd patients.


1989 ◽  
Vol 61 (01) ◽  
pp. 111-116
Author(s):  
Sharron L Pfueller ◽  
Robyn A Bilston ◽  
Dana Logan ◽  
Rosemary David ◽  
Ian G Sloan ◽  
...  

SummaryReactivity of quinine- and quinidine-dependent antiplatelet antibodies has been compared in platelet-rich-plasma (PRP) from normal donors and from patients with von Willebrand’s disease (vWd). One quinine-dependent antibody (Q. Ab) caused platelet aggregation and [14C] serotonin release with only 7 of 12 normal donors, while another Q. Ab and a quinidine-dependent antibody (Qd. Ab) caused aggregation and release with all 12. Drug- dependent IgG binding and PF 3 availability induced by the antibodies were, however, comparable in all donors. Differences in responsiveness were associated with platelets and not plasma. vWd platelets showed normal drug-dependent IgG binding, but decreased aggregation and serotonin release to most drug- dependent antibodies. Responsiveness was not restored by purified vWf:Ag, but, in one case, was corrected by normal plasma or cryoprecipitate. Drug-dependent binding of the Q. Ab which caused variable responsiveness in normals was to the same platelet antigens (GPIb and GPIIIa) in both normal and vWd platelets and did not require plasma components. Reduced PF 3 availability was seen with some antibodies in some vWd patients. Plasma from two of these patients inhibited aggregation of normal platelets to Q. Ab and one of these inhibited aggregation to ADP. Antiplatelet antibodies were detected in these two plasmas by ELISA. Thus some Q. Ab produce different responses with platelets from different donors. In vWd, reduced responsiveness to Q.Ab and Qd. Ab may result from production of inhibitory antiplatelet antibodies.


1974 ◽  
Vol 31 (03) ◽  
pp. 519-520
Author(s):  
Leo R. Zacharski ◽  
Robert Rosenstein

1978 ◽  
Vol 40 (02) ◽  
pp. 288-301 ◽  
Author(s):  
P Meucci ◽  
I R Peake ◽  
A L Bloom

SummaryFactor VIII-related activities have been studied in platelet fractions in order to try to reconcile the conflicting findings of other workers, and to extend the studies. In platelets from 16 normal subjects procoagulant factor VIII was not detected. The amount of factor VIII-related antigen (FVIIIR: AG) in the cytosol per mg of protein was about twice that in the membrane fraction and about ten times that in the debris fraction. There was no significant difference between the amount of FVIIIR: AG and ristocetin cofactor (RistCof) activity in each fraction. The findings in haemophilic platelets were similar. In von Willebrand’s disease (vWd) one serverely affected patient had no detectable factor VIII related activities in any platelet fraction. In 5 patients with intermediate vWd results were normal. In a further 5, with more prolonged bleeding times, no FVIIIR: RistCof was detected in platelets, despite a normal amount of FVIIIR: AG in the cytosol and debris. The electrophoretic mobility of cytosol FVIIIR: AG was increased in all normals and patients, while that in the membrane and debris fractions had normal mobility. Cytosol FVIIIR: AG eluted later than normal FVIIIR: AG on gel filtration on Sepharose 2B, and also showed reduced antibody binding in an immunoradiometric assay. Precipitation of FVIIIR: AG by concanavalin A was incomplete in all platelet fractions from normals, and even more reduced in vWd platelet fractions. The results suggest the possibility of two types of platelet FVIIIR: AG.A factor VIII-related antigen was shown to be associated with normal washed platelets by immunofluorescence techniques (Bloom et al. 1973). Since then, several studies have been reported on the localisation of factor VIII related antigen (FVIIIR: AG), factor VIII procoagulant activity (FVIII: C) and factor VIII related ristocetin cofactor activity (FVIIIR: RistCof) within the platelets. Initially, Howard et al. (1974) indicated that FVIIIR: AG was firmly bound to the platelet membrane, and noted that in lysed platelets the level of FVIIIR: AG as measured by electroimmunodiffusion was higher than that in whole platelet suspensions. However, further studies by Nachman and Jaffe (1975) showed that FVIIIR: AG was also present to a considerable extent in the granules, and they detected none in the platelet cytosol. Bouma and colleagues (1975) were, however, able to find FVIIIR: AG and FVIIIR: RistCof in the cytosol upon freezing and thawing platelets. This FVIIIR: AG had an electrophoretic mobility comparable to that of normal plasma. They also noted that platelets which were air dried apparently had a granular FVIIIR:AG localisation by immunfluorescence; however, intact platelets in suspension did not stain by this method.Recently Ruggeri et al. (1977) and Sultan et al. (1977) have also found FVIIIR: AG in the cytosol, and the former authors reported it to have increased electrophoretic mobility when compared to normal plasma FVIIIR:AG. Results concerning the localisation of FVIIIR: AG in normal platelets have thus been conflicting. Similarly, in the few reports available concerning platelet FVIIIR: AG in von Willibrand’s disease variable results have also been obtained (Ruggeri et al. 1977, Howard et al. 1974, Shearn et al. 1974 and Bouma et al. 1975).In this study we report on the localisation of factor VIII-related activities in normal, haemophilic and von Willebrand’s disease platelets using available standard techniques as well as precipitation of FVIIIR: AG with the plant lectin concanavalin A, a procedure which has been shown to detect abnormal forms of FVIIIR:AG in certain types of von Willebrand’s disease (Peake and Bloom 1977).


1974 ◽  
Vol 31 (02) ◽  
pp. 328-338
Author(s):  
M. M. P Paulssen ◽  
H. L. M. A Vandenbussche-Scheffers ◽  
P. B Spaan ◽  
T de Jong ◽  
M. C Planje

SummaryFactor VIII occurs in the body in two different forms. In lymph factor VIII is bound to chylomicra. In plasma, factor VIII is bound to a protein.After delipidation of chylomicra we obtained a glycoprotein with a high polysaccharide content and a molecular weight of approx. 160,000.In plasma, factor VIII is attached to a protein which is present in normal concentrations in plasma of patients with haemophilia A and in serum (co-factor VIII).This factor is deficient in both the plasma and the serum of patients with von Willebrand’s disease.The binding between factor VIII and co-factor VIII is reversible.Some properties of these two factors are described.


1967 ◽  
Vol 18 (01/02) ◽  
pp. 040-056 ◽  
Author(s):  
E. J Walter Bowie ◽  
P Didisheim ◽  
J. H Thompson ◽  
C. A Owen

SummaryPatients (from 5 kindreds) with variants of von Willebrand’s disease are described. In one kindred the depression of factor VIII was moderate (20 to 40% of normal) and transfusion of 500 ml of normal plasma led to an increase higher than anticipated and to an almost normal level of factor VIII 17 to 24 hrs later. This represents the usual type of von Willebrand’s disease.In the second kindred the concentration of factor VIII was less than 2 % of normal in the son and daughter, who had severe bleeding and hemarthroses.The third kindred was characterized by reduction of factor VIII and a long bleeding time as well as by a serum defect in the thromboplastin-generation test comparable to that seen in patients with hemophilia B, yet with normal levels of factors IX, X, and VII. The severity of the serum defect, the positive result with the Rumpel-Leede test, and the reduced platelet activity in the thromboplastin-generation test are all compatible with the diagnosis of thrombopathy or ‘‘thrombopathic hemophilia.” In two other kindreds, one patient had a long bleeding time and normal levels of factor VIII and another had a normal bleeding time and decrease of factor VIII. The last patient had the type of response to transfusion usually seen in von Willebrand’s disease.In four kindreds, platelet adhesiveness in vivo was found to be strikingly abnormal (virtually absent).It would appear, therefore, that von Willebrand’s disease forms a spectrum, and whether the kindreds reported simply reflect variations of a single genetic disease state or represent separate entities will be answered only by clarification of the underlying etiology of that disease.


1986 ◽  
Vol 55 (03) ◽  
pp. 338-341 ◽  
Author(s):  
H Takahashi ◽  
W Tatewaki ◽  
M Hanano ◽  
R Nagayama ◽  
A Shibata

SummaryPlatelet-type von Willebrand’s disease (vWD) is a bleeding disorder characterized by a heightened interaction between platelets and von Willebrand factor (vWF) as the result of an intrinsic platelet abnormality (probably in GPIb). Platelet aggregability was nearly normal in response to thrombin, wheat germ agglutinin and Ricinus communis agglutinin in this disorder. Unmodified platelets showed no aggregation upon the addition of peanut agglutinin. Partially purified human vWF induced little aggregation of washed patient platelets, but the aggregation was greatly enhanced in the presence of plasma devoid of vWF. Monoclonal antibodies directed against GPIb and GPIIb/IIIa as well as EDTA completely inhibited vWF-induced aggregation. These results indicate that human vWF induces aggregation of platelet-type vWD platelets in the presence of divalent cations and some plasma cofactor(s), and that both GPIb and GPIIb/IIIa are involved in this aggregation.


1979 ◽  
Vol 42 (03) ◽  
pp. 848-854 ◽  
Author(s):  
Paul M Ness ◽  
Herbert A Perkins

SummaryAn enzyme immunoassay (EIA) system has been developed to measure factor VIII- related antigen (VIIIAGN). This assay gives similar results to the commonly used Laurell electroimmunodiffusion (EID) assay for VIIIAGN as shown by comparison of both techniques with samples from healthy controls, patients with hemophilia A, and patients with von Willebrand’s disease. The assay also has a greater precision than the EID technique as demonstrated by multiple assays of aliquots of a single sample. The use of this EIA test for VIIIAGN is simple and employs inexpensive reagents and equipment. The use of expensive antisera is minimized. EIA for VIIIAGN has the advantage of increased sensitivity compared to Laurell EIA.


Sign in / Sign up

Export Citation Format

Share Document